The U.S. Army is funding the GeoVax's preclinical work for the Lassa Fever Vaccine Program Funding the dev and evaluation through non-human primate studies + production of vaccine material for potential human trials
#Lassafever
$GOVX
@USArmy
To the body, GeoVax's VLP antigens look like the naturally-occurring infection. This initiates both cellular and humoral immune response, resulting in a specific and robust immunity that is rapid-acting and highly durable.
#VLP
#virus
#immunity
$GOVX
Ebola virus vaccine is ready to proceed into clinical development, and has demonstrated 100% protection from a single-dose without any adjuvants necessary
#Ebola
#Virus
#Vaccine
$GOVX
Virus Variant From South Africa Detected in US for First Time. GeoVax vaccines produced on the MVA-VLP platform are safe, highly immunogenic, stable at refrigerator temperatures.
#Virus
#development
#SouthAfrica
Unlike conventional cancer therapies, cancer vaccines have the potential to induce responses that help control tumors but also establishes immunological memory that can suppress and prevent tumor recurrence.
#cancer
#vaccines
#immunology
$GOVX
GeoVax has conducted six human trials of the MVA-VLP platform in more than 500 subjects with no serious adverse reactions. GeoVax's MVA-VLP platform and approach is well documented and validated.
#humantrials
#validation
#MVA
-VLP
#vaccines
#cancer
$GOVX
Ebola virus vaccine is ready to proceed into clinical development, and has demonstrated 100% protection from a single-dose without any adjuvants necessary
#Ebola
#Virus
#Vaccine
$GOVX
Publication of Lassa Fever Vaccine Study Results First report showing that a single dose of a replication-deficient MVA vector can confer full protection against a lethal challenge.
#Lassafever
#vaccine
$GOVX
Cases of deadly coronavirus spike as officials confirm human-to-human spread - the need for vaccines against emerging diseases is never-changing. GeoVax's
#MVA
-VLP
#platform
can respond safely and quickly to
#epidemics
$GOVX
#coronavirus
The Global Preparedness Monitoring Board (GPMB) report summary is simple: the world is not prepared for the next pandemic! Working together worldwide in a collaborative, collegial commitment, we can overcome..
#pandemic
#vaccines
#prevention
$GOVX
@WHO
GOVX- B11 for Clade B
#HIV
#Prevention
is Fully Taxpayer Funded. Shouldn't this Vaccine Candidate be Included in National efforts to Eliminate HIV? Phase II. Ready for Pivotal trials. Ending the HIV Epidemic: A Plan for America
@HHSGov
@HIVGov
$GOVX
With cGMP Master Seed Virus of GEO-MVA produced, GeoVax is working to assist in the Mpox global health emergency. Having accomplished this critically important step advances the possibility of expanded
#Mpox
vaccine supply relative to this emergency. $GOVX
Patient enrollment for the UCSF, amfAR, AGT and GeoVax collaborative HIV "Functional Cure" clinical trial is expected to commence during late 2020.
#COVID
-19
#infectiousdiseases
#HIV
#vaccines
$GOVX
COVID-19 vaccine highlights: based on MVA-VLP technology which enables insertion of multiple antigen fragments, potentially allowing for broad-spectrum virus prevention
#COVID19
#vaccine
#IP
$GOVX
Unlike conventional cancer therapies, cancer vaccines have the potential to induce responses that help control tumors but also establishes immunological memory that can suppress and prevent tumor recurrence.
#cancer
#vaccines
#immunology
$GOVX
MVA vaccines provide surprising level of immunogenicity and protective capacity when compared to replicating VACV vector vaccines expressing the same recombinant genes.
#MVA
#characteristics
#betterway
#vaccines
Coronavirus Live Updates: More U.S. Cases Emerge, as China's Death Toll Rises
#nCoV
-2019
#coronavirus
will likely continue to spread. This is serious $GOVXD $GOVX
@NYTimes
GeoVax Immuno-Oncology Programs: The MVA vector platform is well-suited for development of therapeutic cancer vaccines based on the expression of tumor-associated antigens such as MUC1, Cyclin B1 or others
#immunooncology
#vaccine
#development
$GOVX
GeoVax recently announced the initiation of a Phase 1 clinical study of a combination therapy in HIV-positive patients utilizing novel boost component MVA62B
#HIV
#patients
#vaccine
$GOVX
Georgia ranks the highest in new diagnoses in the U.S. and third highest in HIV risk. Importantly, a Georgia company, Geovax is preparing its HIV Vaccine for human trials. Look for
@Geovax_news
at these scientific conferences.
Disease X dummy run: World health experts prepare for a deadly pandemic and its fallout GeoVax's vector platform is perfectly suited to prevent spread of deadly disease X. Safe. Effective. Single Dose. $GOVX
GeoVax's cancer immunotherapy program is built on the idea of combining a tumor‐associated antigen vaccine with a potent anti‐tumor agent
#cancer
#tumors
#antigens
#vaccine
$GOVX
GeoVax's recently initiated Phase I study is designed to induce remission in HIV-positive individuals, also known as a “functional cure.”
#HIV
#patients
#vaccine
$GOVX
Lassa Fever Vaccine Confers Full-Protection With 1-Dose
#Lassa
fever cases surpass
#Ebola
,
#Marburg
, and all other hemorrhagic fevers except
#Dengue
, in its public health impact. $GOVX